Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Progressive supranuclear palsy

Progressive supranuclear palsy

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Progressive supranuclear palsy

6 trials tracked for Progressive supranuclear palsy.

6Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 3 Phase 1 1 Other / NA 2
  1. Phase 2 GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) Completed
  2. Phase 2 Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy Completed
  3. Phase 2 A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Completed
  4. Phase 1 Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers Completed
  5. N/A In-Home Care for Patients With PSP and Related Disorders Completed
  6. N/A Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
QSM MRI reveals distinct iron deposition patterns differentiating Parkinsonian syndromes
Neurology Meta-analysis
QSM MRI reveals distinct iron deposition patterns differentiating Parkinsonian syndromes Brain MRI technique may help tell apart Parkinson's and similar disorders
This systematic review and meta-analysis of 626 PD, 160 MSA, 176 PSP patients and 256 controls found that quantitative susceptibility mappin…
A special MRI can spot distinct brain iron patterns in Parkinson's and related diseases, offering a potential diagnostic tool.
Jun 1, 2026
Florzolotau PET shows tau accumulation patterns and links to progression in progressive supranuclear palsy
Neurology
Florzolotau PET shows tau accumulation patterns and links to progression in progressive supranuclear palsy New Scan Tracks PSP Brain Changes Year by Year
This longitudinal observational study evaluated florzolotau (18F) PET imaging in 26 patients with progressive supranuclear palsy and 10 heal…
A new brain scan tracks how PSP disease spreads over time to help doctors measure treatment success without waiting for symptoms to change.
medRxiv Apr 28, 2026
6-metabolite blood biomarkers aid differential diagnosis of Parkinson's disease versus healthy controls and other neurodegenerative conditions
Neurology
6-metabolite blood biomarkers aid differential diagnosis of Parkinson's disease versus healthy controls and other neurodegenerative conditions Can a simple blood test tell the difference between Parkinson's and other brain diseases?
This observational study assessed a 6-metabolite blood biomarker (6M-BB) profiled by 1H NMR for distinguishing Parkinson's disease (PD) from…
A simple blood test using six metabolites correctly identified Parkinson's disease in nearly 95% of cases while distinguishing it from other…
medRxiv Apr 9, 2026